Compare Abeona Therapeutics Inc (ABEO) vs Vanguard S&P 500 Growth Index Fund ETF (VOOG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Vanguard S&P 500 Growth Index Fund ETF — how do they compare? Abeona Therapeutics Inc trades at $6.74 (market cap $373.32M), while Vanguard S&P 500 Growth Index Fund ETF trades at $81.64. Which is the better fit depends on your goals.
| ABEO | VOOG | |
|---|---|---|
Market Cap | $373.32M | — |
Sector | Health | Broad Market / Factor |
52-Week High | $7.23 | $85.11 |
52-Week Low | $4.17 | $65.32 |
Enterprise Value | $228.22M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
VOOG trades at $82.41, up 1.22% today, with a bullish technical outlook from moving averages but neutral oscillators. The ETF completed a 1:6 stock split in April 2026 to enhance accessibility. Recent news highlights its low 0.07% expense ratio and strong long-term growth focus on S&P 500 constituents, though short interest rose significantly in March 2026.
Outlook remains positive due to cost efficiency and growth stock exposure, but risks include tech sector volatility and high valuations. Investors benefit from diversification but should monitor market sentiment shifts amid economic uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Vanguard S&P 500 Growth Index Fund ETF
VOOG is an index-based ETF that tracks the S&P 500 Growth Index, composed of the growth-oriented companies within the S&P 500. It selects constituents based on three key metrics—sales growth, the ratio of earnings change to price, and momentum—offering a highly liquid and low-cost way to capture the high-performing 'growth slice' of the broader U.S. large-cap market.
Read more on VOOG →
